Angelman Syndrome
Also known as: AS, Happy Puppet Syndrome
Angelman syndrome is a complex genetic disorder that primarily affects the nervous system. It is characterized by severe intellectual disability, delayed development, problems with movement and balance (ataxia), seizures, and a generally happy demeanor with frequent smiling and laughter. Individuals with Angelman syndrome typically have a small head size (microcephaly) and fair skin with light-colored hair.
Angelman Syndrome is a genetic condition that makes kids have trouble with talking, walking, and learning. They often smile and laugh a lot and seem very happy, but they need extra help to grow and develop.
Signs & Symptoms
- Severe intellectual disability
- Developmental delay
- Speech impairment (minimal or no speech)
- Movement and balance problems (ataxia)
- Seizures
- Frequent smiling and laughter
- Microcephaly
- Fair skin and light hair (in some cases)
- Sleep disturbances
- Hyperactivity
- Fascination with water
- Protruding tongue
- Wide-based gait
- Hand flapping
Treatment Options
Anti-epileptic drugs (AEDs)
MODERATELY EFFECTIVEPhysical therapy
SUPPORTIVEOccupational therapy
SUPPORTIVESpeech therapy
SUPPORTIVEBehavioral therapy
SUPPORTIVESleep management strategies
SUPPORTIVEGene Therapy (experimental)
EXPERIMENTALDiagnosis
- Clinical evaluation
- Genetic testing (DNA methylation analysis, UBE3A sequencing, chromosomal microarray)
- Electroencephalogram (EEG)
History
Angelman syndrome was first described by Dr. Harry Angelman in 1965, who observed three children with similar characteristics. He initially referred to the condition as 'Happy Puppet Syndrome' due to their jerky movements and frequent smiling. The genetic basis of the syndrome was later discovered in the late 1980s and early 1990s.
Recent Breakthroughs
ASO Therapy Shows Promise in Angelman Syndrome
Antisense oligonucleotide (ASO) therapy targeting the paternal UBE3A allele to unsilence it is showing promising results in clinical trials, with improvements in motor function, communication, and behavior observed in some patients.
Gene Therapy Approaches for Angelman Syndrome
Researchers are actively exploring gene therapy strategies to deliver a functional copy of the UBE3A gene to neurons in individuals with Angelman syndrome. Preclinical studies have shown encouraging results.